Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: Labrador who wrote (211)	4/11/1998 9:59:00 PM
From: Haolin Ni	Read Replies (2) \| Respond to of 712

Yes, I agree with you. The FDA Committee Recommends Approval of Merck's Platelet Blocker Aggrastat(R) for the Treatment of Unstable Angina is not a good news for CORR. Remember that FDA Committee did not recommend approval INTEGRILIN of CORR to be used for unstable angina few months back. The production and market abilities of MRK, LLY and CNTO are far better than CORR so that CORR will not get big part of the pie.

To: Labrador who wrote (211)	4/12/1998 1:45:00 AM
From: shortlong2	Respond to of 712

The portion of the news release that I posted was to point out to quite a few people that the MRK news release DOES NOT STATE THAT THE FDA HAS APPROVED MRK's AGGRASTAT, IT HAS ONLY BEEN BACKED BY AN ADVISORY PANEL ..........WHICH IS NOT THE FDA ITSELF.....now bob if you would care to view quite a few post's both here and on the YAHOO mb you will plainly see that many people think that MRK has already gotten FDA approval when in fact that is not a fact. Are you also one of these people?? So my point is that I am NOT trying to mislead anybody, I am simply highlighting something that they are misreading........Do you understand me now?? Bill